| imatinib / Generic mfg. |
NCT00006357: STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma |
|
|
| Completed | 2 | 91 | Europe | imatinib mesylate | European Organisation for Research and Treatment of Cancer - EORTC | Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer, Sarcoma, Small Intestine Cancer | 04/01 | | | |
NCT00042952: Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer |
|
|
| Terminated | 2 | 32 | US | imatinib mesylate, CGP 57148, Gleevec, Glivec, therapeutic conventional surgery, laboratory biomarker analysis | National Cancer Institute (NCI) | Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma | 10/03 | | | |
NCT00216112: Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer |
|
|
| Completed | 2 | 23 | US | Imatinib Mesylate, Docetaxel | Daniela Matei, MD, Novartis Pharmaceuticals, Sanofi, Walther Cancer Institute | Ovarian Cancer | 10/05 | 07/07 | | |
NCT00039585: Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor |
|
|
| Completed | 2 | | US | imatinib mesylate | National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 02/06 | | | |
NCT00041041: Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 60 | US | imatinib mesylate, CGP 57148, Gleevec, Glivec, laboratory biomarker analysis | National Cancer Institute (NCI) | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | 01/07 | | | |
NCT00036751: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 40 | US | imatinib mesylate, CGP 57148, Gleevec, Glivec, laboratory biomarker analysis | National Cancer Institute (NCI) | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | 08/07 | | | |
NCT00840450: Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin |
|
|
| Terminated | 2 | 14 | US | Gleevec/Paclitaxel, Gleevec:Imatinib Mesylate, Paclitaxel: Taxol | NYU Langone Health, Novartis | Ovarian Cancer | 04/10 | 10/12 | | |
NCT00928642: Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer |
|
|
| Completed | 2 | 8 | US | imatinib mesylate by mouth, Gleevec, Gemcitabine Intravenous, Gemzar | Henry M. Jackson Foundation for the Advancement of Military Medicine, Novartis | Ovarian Cancer, Primary Peritoneal Cancer | 11/10 | 11/10 | | |
| Completed | 2 | 73 | US | Imatinib Mesylate, Imatinib, Gleevec, STI571, NSC-716051 | M.D. Anderson Cancer Center | Ovarian Cancer | 02/12 | 02/12 | | |
|
